Ulcerative Colitis Clinical Trial
Official title:
Special Physical Exercises as a Therapeutic Intervention for Inflammatory Bowel Disease
NCT number | NCT04303260 |
Other study ID # | 0277-18-TLV |
Secondary ID | |
Status | Recruiting |
Phase | N/A |
First received | |
Last updated | |
Start date | July 8, 2019 |
Est. completion date | December 2025 |
The investigator is hypothesize that physical activity can have positive effects on health, general well-being , sleep quality and stress in Inflammatory Bowel Disease patients.
Status | Recruiting |
Enrollment | 50 |
Est. completion date | December 2025 |
Est. primary completion date | August 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 60 Years |
Eligibility | Inclusion Criteria: 1. 18 < age < 60 2. Clinically stable patients, constant medicinal regimen throughout the study period. Refractory to mesalamine at least 6 weeks, or steroids at least 2 week, or immunomodulator at least 12 weeks or biologics at least 12 weeks therapy, medical cannabis at least 2 weeks before the study. 3. CD patients will be included if their symptoms score 5= between =15 on the Harvey-Bradshaw index (HBI) score 4. UC patients will be included if their symptoms score 3=between=9 on the Simple Clinical Colitis Activity Index (SCCAI) Exclusion Criteria: 1. Inability to commit for performing at least 15 minutes of exercise, 6 times a week 2. Lack of availability or capability to use a computer/ internet. 3. Any proven current infection such as Clostridium difficile infection, positive stool culture, or parasites. 4. Inability to sign informed consent and complete study protocol 5. Pregnancy 6. Subjects with chronic conditions such as cancer, organ transplant subjects, advanced kidney or liver disease, systemic inflammatory conditions other than IBD. 7. Patients with ileostomy, pouch or short bowel |
Country | Name | City | State |
---|---|---|---|
Israel | Dep. of Gastroenterology, Tel Aviv Sourasky Medical Center | Tel Aviv |
Lead Sponsor | Collaborator |
---|---|
Tel-Aviv Sourasky Medical Center |
Israel,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Clinical response assessed by a change in HBI | Doctor evaluation -The Harvey-Bradshaw index activity index
Harvey Bradshaw Index (based on the day before): General well-being: very well =0 slightly below par =1 poor =2 very poor =3 terrible =4 Abdominal pain: none =0 mild =1 moderate =2 severe =3 Abdominal mass: none =0 dubious =1 definite =2 definite and tender =3 Number of liquid stools per day: Complications: none =0 arthralgia =1 uveitis =1 erythema nodosum =1 aphthous ulcers =1 pyoderma gangrenosum =1 anal fissure =1 new fistula =1 abscess =1 SCORE: <5 Remission 5-7 Mild activity 8-16 Moderate activity >16 Sever activity |
After 4 weeks | |
Primary | Clinical response as assessed by a change in SCCAI | Doctor evaluation- Simple Clinical Colitis Activity Index
Bowel frequency (day): 0-3 / day (0) 4-6 / day (1) 7-9 / day (2) >9 / day (3) Bowel frequency (night): 0 / night (0) 1-3 / night (1) 4-6 / night (2) General well being: very well (0) slightly below par (1) poor (2) very poor (3) terrible (4) Urgency of defecation: none (0) Hurry (1) Immediately (toilet nearby) (2) Incontinence (3) Blood in stool: None (0) Trace (1) Occasionally (<50% of defecations) (2) Usually (>50% of defecations) (3) SCCAI Score: (add scores of questions 1 to 5) Remission<3 Mild Disease 3-5 Moderate Disease 6-9 Severe Disease =10 |
After 4 weeks | |
Primary | Clinical response as assessed by a change in PROMIS questionnaire | PROMIS (Patient-Reported Outcomes Measurement Information System) | After 4 weeks | |
Primary | Clinical response as assessed by a change in QOL questionnaire | Quality of life questionnaire | After 4 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05702879 -
Combined Microbiota and Metabolic Signature in Ulcerative Colitis Predicts Anti-Inflammatory Therapy Success
|
||
Not yet recruiting |
NCT05953402 -
A Study of Ozanimod in Pregnant Women With Ulcerative Colitis and Their Offspring
|
||
Recruiting |
NCT05316584 -
A Novel Remote Patient and Medication Monitoring Solution to Improve Adherence and PerSiStence With IBD Therapy
|
N/A | |
Recruiting |
NCT03950232 -
An Extension Study for Treatment of Moderately to Severely Active Ulcerative Colitis
|
Phase 3 | |
Completed |
NCT03124121 -
Study of the Golimumab Exposure-Response Relationship Using Serum Trough Levels
|
Phase 4 | |
Not yet recruiting |
NCT06100289 -
A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease
|
Phase 3 | |
Withdrawn |
NCT04209556 -
A Study To Evaluate The Safety And Efficacy Of PF-06826647 In Participants With Moderate To Severe Ulcerative Colitis
|
Phase 2 | |
Terminated |
NCT00061282 -
Clotrimazole Enemas for Pouchitis in Children and Adults
|
Phase 1/Phase 2 | |
Recruiting |
NCT04398550 -
SCD vs. Mediterranean Diet Therapy in Ulcerative Colitis
|
N/A | |
Recruiting |
NCT04314375 -
Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Budesonide Extended-release Tablets in Pediatric Subjects Aged 5 to 17 Years With Active, Mild to Moderate Ulcerative Colitis
|
Phase 4 | |
Active, not recruiting |
NCT04857112 -
Study Evaluating Efficacy and Safety of Amiselimod (MT-1303) in Mild to Moderate Ulcerative Colitis
|
Phase 2 | |
Completed |
NCT05051943 -
A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response
|
||
Active, not recruiting |
NCT04033445 -
A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis
|
Phase 2/Phase 3 | |
Recruiting |
NCT05428345 -
A Study of Vedolizumab SC Given to Adults With Moderate to Severe Ulcerative Colitis or Crohn's Disease in South Korea
|
||
Active, not recruiting |
NCT06221995 -
Energy Expenditure in Patients With Ulcerative Colitis Undergoing Surgery
|
||
Recruiting |
NCT04767984 -
Testing Atorvastatin to Lower Colon Cancer Risk in Longstanding Ulcerative Colitis
|
Phase 2 | |
Completed |
NCT02508012 -
Medico-economic Evaluation of the Therapeutic Drug Monitoring of Anti-TNF-α Agents in Inflammatory Bowel Diseases
|
N/A | |
Recruiting |
NCT06071312 -
FMT in Patients With Recurrent CDI and Ulcerative Colitis: Single Infusion Versus Sequential Approach
|
Phase 1/Phase 2 | |
Completed |
NCT03760003 -
Dose-Ranging Phase 2b Study of ABX464 in Moderate to Severe Ulcerative Colitis
|
Phase 2 | |
Not yet recruiting |
NCT05539625 -
Mini-MARVEL - Mitochondrial Antioxidant Therapy in Ulcerative Colitis
|
Phase 2 |